Keros Therapeutics (KROS) vs ProQR Therapeutics N.V. (PRQR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Keros Therapeutics (KROS) has outperformed ProQR Therapeutics N.V. (PRQR) over the past year, losing 25.9% versus a loss of 34.8%. Over five years, KROS leads with a -69.4% price change compared with -79.3% for PRQR. Keros Therapeutics is the larger company by market cap ($236.9 million vs $230.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | PRQR |
|---|---|---|
| Share price | $11.95 | $1.63 |
| Market cap | $236.93M | $230.02M |
| 1-day change | +2.66% | +3.82% |
| YTD return | -41.31% | -19.31% |
| 1-year return | -25.87% | -34.80% |
| 5-year return | -69.35% | -79.31% |
| EPS (TTM) | $-3.22 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.55 | $3.10 |
| 52-week low | $9.69 | $1.33 |
| Distance from 52-week high | -47.01% | -47.42% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +65.94% | +377.30% |
| Average volume | 194.05K | 796.41K |
| Shares outstanding | 19.83M | 141.12M |
| Employees | 92 | 186 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
KROS vs PRQR FAQ
Which is bigger, Keros Therapeutics or ProQR Therapeutics N.V.?
Keros Therapeutics (KROS) is larger, with a market capitalization of $236.93M compared with $230.02M for ProQR Therapeutics N.V. (PRQR).
Which stock has performed better over the past year, KROS or PRQR?
KROS returned -25.87% over the past 12 months, compared with -34.80% for PRQR (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and ProQR Therapeutics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.